People

Anne  Pereira , Ph.D.

Professor & Assoc. Dean of Research

Department of Pharmaceutical Sciences

405-271-6593  x58034

CPB 329
anne-pereira@ouhsc.edu
Phone
Fax
Office
Email

Education & Experience

Education
  • Postdoctoral fellow/Immunology, Royal Children's Hospital, Melbourne, Australia, 1984-1990.
  • Ph.D., Pathology, University of Melbourne, Australia. 1982.
  • B.Sc. (Hon), Immunology. University of Melbourne, Australia,1976.
  • B.Sc., Microbiology/Pathology. University of Melbourne, Australia, 1975.

Experience

  • Chair and Chief Scientific Officer, Biolytx Pharmaceuticals Corp, OKC, OK, 2006-present
  • President and Chief Scientific Officer, Biolytx Pharmaceutical Corp (commercial development of an antibiotic based on CAP37 peptides for the treatment of severe Gram negative infections), 2005-2006.
  • Adjunct Associate Professor, Depts. of Cell Biology & Surgery, OUHSC, OKC, OK, 1999-present
  • Associate Professor with tenure, Dept. of Pathology, OUHSC, OKC, OK, 1997-2009
  • Assistant Professor, Dept. of Pathology, OUHSC, OKC, OK, 1992-1997
  • Assistant Professor, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1991-1992
  • Senior Research Associate, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1984-1990.

 

Honors & Service

Honors
  • Henry Zarrow Presidential Professorship for meeting the highest standards of excellence in scholarship and teaching, 2008.
  • Chair, minisymposium "Host pathogen interactions and toll-like receptors." Experimental Biology 2008, San Diego, CA.
  • Finalist, Grace & Franklin Bernsen Foundation; Most Promising New Business Award to Biolytx Pharmaceuticals Corp., 2007.
  • "On the brink award winner," Journal Record Innovator of the Year award, 2006.
  • Co-chair, minisymposium "Innate and acquired immunity," Experimental Biology, 2006, San Francisco, CA.
  • Discussion Leader, "Vascular Wall," Experimental Biology 2003, San Diego, CA.
  • Chair, "Mediators of Inflammation," Experimental Biology 2000, San Diego, CA.

Service

  • NIH Anterior Eye Disease Member Conflict (ZRG1-BDCN F02 M), Feb. 17-18, 2009.
  • NIH Brain Disorders and Clinical Neuroscience (ZRG!BDCN-F02) study section, Oct. 10, 2008.
  • NIH/NEI Anterior Eye Disease study section - ad hoc reviewer, Oct. 6-7, 2008.
  • American Society for Investigative Pathology (ASIP) Program Committee member for Experimental Biology (EB 2007 & CB 2008).
  • NIH, Brain Disorders and Clinical Neuroscience BDCN-3 Study Section - ad hoc reviewer.

Current Grants Awarded

  • Development of an antimicrobial peptide therapeutic for Pseudomonas infections. The major goals of this project are to perform the critical pre-clinical experiments required to advance a novel antibiotic peptide for the treatment of hospital acquired infections into clinical trials. NIH/NIAID 1U01 A1075391, 09/01/07-08/31/12.
  • CAP37 and ocular inflammation. The major goals of this project are to determine the biological significance of the innate immune system molecular, CAP37, in corneal inflammation and to investigate its therapeutic potential for treatment of corneal wounds and infections. NIH/NEI 1R01 EY 015534-01A2, 09/30/07-08/31/12.
  • New therapeutics based on a natural antibiotic peptide. To use a primate model for the evaluation of a novel antibiotic peptide based on CAP37 to treat serious Gram negative infections and sepsis. OCAST/OARS, 03/01/08-02/28/10.
  • Molecular basis of immunity. For training graduate students and postdoctoral fellows in immunology. NIH/NIAID IP32-A107633-06 (Cunningham PI), 09/01/06-03/31/11.